Palobiofarma has completed the dose escalation of the Phase I clinical trial evaluating the safety and tolerability of the novel PDE10/A2a dual antagonist PBF-999 in patients with solid tumors. The trial has been conducted at the Vall D Hebron Hospital, in Barcelona, Spain. The product has...